Tier 2 — strong

Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial

Norheim KL, Ben Ezra M, Heckenbach I, Andreasson LM, Eriksen LL, Dyhre-Petersen N, Damgaard MV, Berglind M, Pricolo L, Sampson D, Dellinger RW, Sverrild A, Treebak JT, Ditlev SB, Porsbjerg C, Scheibye-Knudsen M
Nature aging 2024 4; 12; 1772-1781

Bibliography

PubMed
PMID 39548320
PubMed Central
PMC11645284
DOI
10.1038/s43587-024-00758-1
Funding
Funding/support listed in the publication: Bredgade 40-42 DK - 1260 Copenhagen K Phone: +45 3392 9700 Email: ufm@ufm.dk.
Competing interests
Two authors reported Elysium Health employment and share ownership.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample40 patients with stable COPD
InterventionNR 2000 mg/day versus placebo
Duration6 weeks; follow-up 12 weeks after treatment
EndpointsSputum IL-8; blood NAD+; exploratory airway pathways

What the study showed, in plain terms

NR reduced the primary sputum IL-8 measure and increased whole-blood NAD+ in this small COPD trial.

Key findings

The estimated IL-8 treatment difference at six weeks was −52.6%.

What this study can and cannot tell us

Inflammatory and exploratory epigenetic findings do not establish fewer exacerbations, better lung function or reduced mortality.

Related papers in the corpus

Tier 4
NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis
Han K et al. · JCI insight · 2026
Tier 4
Nicotinamide Riboside Augments Human Macrophage Migration via SIRT3-Mediated Prostaglandin E2 Signaling
Wu J et al. · Cells · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology